MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

Search

Artivion Inc

Gesloten

SectorGezondheidszorg

30.08 -1.96

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

29.95

Max

30.78

Belangrijke statistieken

By Trading Economics

Inkomsten

16M

-505K

Verkoop

1.7M

99M

EPS

-0.012

Winstmarge

-0.51

Werknemers

1,600

EBITDA

2.7M

2.1M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+7.42% upside

Dividenden

By Dow Jones

Volgende Winsten

7 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

471M

1.5B

Vorige openingsprijs

32.04

Vorige sluitingsprijs

30.08

Artivion Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 jul 2025, 15:29 UTC

Belangrijke Marktbewegers

Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment

7 jul 2025, 23:44 UTC

Marktinformatie

Nikkei May Fall on U.S. Tariff Concerns -- Market Talk

7 jul 2025, 23:44 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 jul 2025, 23:41 UTC

Marktinformatie

Gold Edges Lower Amid Hopes for Possible Trade Agreements -- Market Talk

7 jul 2025, 23:19 UTC

Marktinformatie

Global Equities Roundup: Market Talk

7 jul 2025, 23:19 UTC

Marktinformatie

AML3D Bull Sees Navy Letter Lowering Risks -- Market Talk

7 jul 2025, 22:20 UTC

Marktinformatie

Global Equities Roundup: Market Talk

7 jul 2025, 22:20 UTC

Marktinformatie

AT&T's Fiber Strategy Positions Stock to Outperform -- Market Talk

7 jul 2025, 21:34 UTC

Acquisities, Fusies, Overnames

BlackRock's Latest Acquisition Is a Commercial Real Estate Bet -- Barrons.com

7 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

7 jul 2025, 20:45 UTC

Acquisities, Fusies, Overnames

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7 jul 2025, 20:16 UTC

Marktinformatie

Canada Bonds Set to Benefit From Rotation Away U.S. Assets -- Market Talk

7 jul 2025, 19:37 UTC

Marktinformatie

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

7 jul 2025, 19:12 UTC

Marktinformatie

Oil Futures Shrug Off Bigger OPEC+ Output Increase -- Market Talk

7 jul 2025, 18:33 UTC

Marktinformatie

Gold Flat as Investors Assess Market Direction -- Market Talk

7 jul 2025, 18:27 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 jul 2025, 16:53 UTC

Winsten

Freight Stocks Have a Tariff Overhang. Morgan Stanley Says It Could Be Worse. -- Barrons.com

7 jul 2025, 16:30 UTC

Marktinformatie

Higher Prices Limit Power Sector's Natural Gas Use -- Market Talk

7 jul 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

7 jul 2025, 16:05 UTC

Acquisities, Fusies, Overnames

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7 jul 2025, 15:41 UTC

Marktinformatie

Gold Futures Fall as Stronger U.S. Dollar Undermines Safe-Haven Demand -- Market Talk

7 jul 2025, 15:41 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

7 jul 2025, 15:40 UTC

Marktinformatie

Base Metal Prices Tick Lower on U.S. Dollar Strength -- Market Talk

7 jul 2025, 15:30 UTC

Marktinformatie

Physical Oil Market Stable But Structural Weakness Looms -- Market Talk

7 jul 2025, 15:18 UTC

Marktinformatie

BNP Cuts Brent Forecast on U.S. Shale, Iran Supply Resilience -- Market Talk

7 jul 2025, 15:14 UTC

Acquisities, Fusies, Overnames

MicroStrategy Goes a Week Without Buying Bitcoin. Saylor Has Advice for Crypto Traders. -- Barrons.com

7 jul 2025, 15:00 UTC

Acquisities, Fusies, Overnames

GSK Completes Acquisition of Efimosfermin

7 jul 2025, 14:52 UTC

Marktinformatie

Dollar Faces Downward Pressures Stemming from Tariffs -- Market Talk

7 jul 2025, 14:51 UTC

Marktinformatie

Bullish Factors Lift Oil Despite Downward Pressure -- Market Talk

7 jul 2025, 14:45 UTC

Marktinformatie

Saudi Arabia Not Seeking to Take Oil Market Share -- Market Talk

Peer Vergelijking

Prijswijziging

Artivion Inc Prognose

Koersdoel

By TipRanks

7.42% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 33 USD  7.42%

Hoogste 35 USD

Laagste 30 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Artivion Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Artivion Inc

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.